Tumor Necrosis Factor-α Gene G-308A Polymorphism Is a Risk Factor for the Development of Membranous Glomerulonephritis

2006 ◽  
Vol 26 (1) ◽  
pp. 12-15 ◽  
Author(s):  
Christos Bantis ◽  
Peter J. Heering ◽  
Sendogan Aker ◽  
Magdalena Siekierka ◽  
Nicola Kuhr ◽  
...  
Keyword(s):  
Risk Factor ◽  
Tumor Necrosis Factor ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Α ◽  
Membranous Glomerulonephritis ◽  
Factor Α ◽  
Necrosis Factor

scholarly journals Tumor necrosis factor α is a risk factor for infection in peritoneal dialysis patients

2016 ◽  
Vol 31 (4) ◽  
pp. 722-729 ◽  
Author(s):  
Eunjung Kang ◽  
Seihran Kim ◽  
Hwa Jung Lee ◽  
Inhwee Park ◽  
Heungsoo Kim ◽  
...  
Keyword(s):  
Risk Factor ◽  
Peritoneal Dialysis ◽  
Tumor Necrosis Factor ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Α ◽  
Dialysis Patients ◽  
Factor Α ◽  
Necrosis Factor

The –308 G/A Tumor Necrosis Factor-α Gene Dimorphism: A Risk Factor for Unstable Angina

2003 ◽  
Vol 41 (4) ◽  
Author(s):  
Virginie Bernard ◽  
Xavier Pillois ◽  
Isabelle Dubus ◽  
Daniel Benchimol ◽  
Jean-Pierre Labouyrie ◽  
...  
Keyword(s):  
Risk Factor ◽  
Tumor Necrosis Factor ◽  
Unstable Angina ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Α ◽  
Factor Α ◽  
Necrosis Factor

scholarly journals Adhesion molecules and urinary tumor necrosis factor-α in idiopathic membranous glomerulonephritis

1998 ◽  
Vol 53 (4) ◽  
pp. 909-917 ◽  
Author(s):  
Eero Honkanen ◽  
Eeva von Willebrand ◽  
Anna-Maija Teppo ◽  
Tom Törnroth ◽  
Carola Grönhagen-Riska
Keyword(s):  
Tumor Necrosis Factor ◽  
Adhesion Molecules ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Α ◽  
Membranous Glomerulonephritis ◽  
Idiopathic Membranous Glomerulonephritis ◽  
Factor Α ◽  
Necrosis Factor

scholarly journals Use of inhibitors of tumor necrosis factor α in women with ankylosing spondylitis

2021 ◽  
Vol 15 (5) ◽  
pp. 44-50
Author(s):  
O. A. Krichevskaya ◽  
T. V. Dubinina ◽  
E. V. Ilyinykh ◽  
A. B. Demina ◽  
I. A. Andrianova
Keyword(s):  
Risk Factor ◽  
Ankylosing Spondylitis ◽  
Tumor Necrosis Factor ◽  
Early Pregnancy ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Α ◽  
Adverse Pregnancy Outcome ◽  
The Third ◽  
Factor Α ◽  
Necrosis Factor

Objective: to present our own experience of tumor necrosis factor α (TNFα) inhibitors (iTNFα) usage during pregnancy in women with ankylosing spondylitis (AS), to assess AS activity and outcomes of gestation.Patients and methods. A prospective observation of 55 pregnant women with AS who met the modified New York criteria of 1984. Fifty-six pregnancies were followed. The average age of the patients was 31.7±4.7 years, the duration of the disease was 132.2±85.4 months. The median BASDAI for pregnancy trimesters was 2.4 [1.2; 4.4], 2.7 [1.4; 4.2] and 2.2 [1.5; 4.0], respectively. 14 women received iTNFα 3 months before pregnancy.Results and discussion. In the first trimester, TNFα was used in 9 (16.1%) patients, in the second – in 9 (16.1%) and in the third – in 5 (9.3%); the median BASDAI for trimesters was 2.3 [1.0; 3.7], 3.4 [1.2; 3.5], 3.0 [0.8; 3.4], respectively. All patients who discontinued iTNFα just before or in early pregnancy had indications for resuming therapy in the second half of gestation. Cancellation of iTNFα at the end of the second trimester was not a risk factor for high activity in the third trimester. There was 1 adverse pregnancy outcome. In other cases, childbirth occurred at 38.9±1.4 weeks, newborns' body weight was 3273.1±435.6 g.Conclusion. Women with AS who plan a pregnancy should be prescribed drugs with the maximum allowed duration of use during gestation. Cancellation of iTNFα before and in early pregnancy is a risk factor for high AS activity, while renewal of iTNFα therapy during pregnancy is not always effective.

Sign in / Sign up

Export Citation Format

Share Document